Providence Capital Advisors, LLC Biogen Inc. Transaction History

Providence Capital Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$217.44 - $243.88 $869 - $975	-4 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$219.29 - $241.72 $4,385 - $4,834	-20 Reduced 83.33%	4 $1,000
Q1 2019 May 08, 2019	BUY	$216.71 - $338.96 $4,334 - $6,779	20 Added 500.0%	24 $6,000
Q4 2017 Feb 12, 2018	BUY	$307.64 - $344.58 $1,230 - $1,378	4	4 $1,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Providence Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Providence Capital Advisors, LLC with notifications on news.